Outcome Evaluation of Gabapentin as Add-on Therapy for Partial Seizures

Canadian Journal of Neurological Sciences

Volumn 25, Issue 2, 1998, Pages 134-140

  Bruni, Joseph ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; PHENYTOIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SEIZURE;

ACETIC ACIDS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINES; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; BENZODIAZEPINONES; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUALITY OF LIFE; VALPROIC ACID;

EID: 0031836358     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100033746     Document Type: Article

References (18)

1. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36 (Suppl. 2): S13-S26.
2. á Rogvi-Hansen B, Gram L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol Ther 1995; 68(3): 425-434.
3. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334(24): 1583-1590.
4. Leach JP, Brodie MJ. New antiepileptic drugs - an explosion of activity. Seizure 1995; 4: 5-17.
5. Andrews CO, Fisher JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1995; 28: 1188-1196.
6. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994; 44 (Suppl. 5): S10-S16.
7. Bruni J. Titration of gabapentin dose for optimal control of epileptic seizures. Adv Therapy 1996; 13(6): 324-334.
8. Bruni J. Gabapentin. Can J Neurol Sci 1996; 23 (Suppl. 2): S10-S12.
9. Proposal for revised Classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1989; 30(4): 389-399.
10. Devinsky O, Cramer JA and the QOLIE Development Group. Professional Postgraduate Services, a division of Physicians World Communications Group, Secaucus, NJ, USA.
11. Wilder BJ. The treatment of epilepsy: an overview of clinical practices. Neurology 1995; 45 (Suppl. 2): S7-S11.
12. Ramsay RE. Gabapentin: Toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th Ed. New York: Raven Press, 1995; 857-860.
13. Willmore LJ. The effect of age on pharmacokinetics of AED's. Epilepsia 1995; 36 (Suppl. 5): S14-S21.
14. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44 (Suppl. 5): S17-S22.
15. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new AED's. Epilepsia 1996; 37 (Suppl. 2): S8-S13.
16. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5: 89-95.
17. Bruni J. Neurontin® as add-on therapy in patients with partial seizures - long term study Proc. World Congress of Neurology [abstract] (in press).
18. Bruni J. Efficacy of gabapentin (Neurontin®) as first add-on therapy in the treatment of partial seizures - long term follow-up [abstract] Epilepsia 1997; 38 (Suppl. 8): S94.